Nevertheless, FISH and microarray-based technologies have contributed to the identification of clinically relevant markers, such as ERBB2 (HER2) amplification in breast cancer, which predicts the response to anti-HER2 therapies such as trastuzumab, or 1p/19q co-deletion in oligodendrogliomas, which inform both the prognosis and therapeutic response [122,123]. This evidence concerns the gene ERBB2 and oligodendroglioma.